Fluoroquinolone-nitro imidazole fixed-dose combination medication-induced fixed drug eruption with positive re-challenge

Debjyoti Halder; Indrani Dalal; Durbashree Das

doi:10.18203/2319-2003.ijbcp20252587

Authors

Debjyoti Halder Department of Pharmacology, Midnapore Medical College, West Bengal, India https://orcid.org/0000-0001-7629-826X
Indrani Dalal Department of Pharmacology, Midnapore Medical College, West Bengal, India
Durbashree Das Department of Biochemistry, Institute of Postgraduate Medical Education and Research, West Bengal, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20252587

Keywords:

Fixed drug eruption, Fixed dose combination, Adverse drug reaction

Abstract

Fluoroquinolone-nitroimidazole fixed-dose combinations, such as ofloxacin-ornidazole and norfloxacin-tinidazole, are widely prescribed for gastrointestinal infections. However, fixed drug eruptions (FDEs) associated with these combinations are underreported. A 32-year-old female developed generalized itching and painful ulcerative lesions on the buccal mucosa shortly after taking an ofloxacin-ornidazole tablet. Upon discontinuation and substitution with norfloxacin-tinidazole by a physician, her symptoms worsened, indicating a positive rechallenge. Dermatological evaluation led to withdrawal of the drug and initiation of antihistamines and topical analgesics, resulting in symptom resolution. Her clinical course, including lesion recurrence at the same site upon re-exposure, confirmed the diagnosis of FDE, a delayed-type hypersensitivity reaction mediated by CD8+ T cells. Causality assessment using the World Health Organization-Uppsala Monitoring Centre (WHO-UMC) scale classified the reaction as certain. This case highlights the need for thorough drug history taking and the importance of avoiding re-prescription of drugs from the same pharmacological class in patients with suspected drug allergies.

Metrics

Metrics Loading ...

References

Chakrabarti A. Prescription of fixed dose combination drugs for diarrhoea. Indian J Med Ethics. 2007;4:165-7. DOI: https://doi.org/10.20529/IJME.2007.065

Buffer DF. Fixed Drug Eruptions: Background, Pathophysiology, Etiology. Medscape. Available at: https://emedicine.medscape.com/article/1336702-overview. Accessed on 15 April 2025.

Pal A, Sen S, Das S, Biswas A, Tripathi SK. A Case of Self-treatment Induced Recurrent Fixed Drug Eruptions Associated with the Use of Different Fixed Dose Combinations of Fluoroquinolone-Nitroimidazole. Iran J Med Sci. 2014;39:584-8.

Sanmukhani J, Shah V, Baxi S, Tripathi C. Fixed drug eruption with ornidazole having cross-sensitivity to secnidazole but not to other nitro-imidazole compounds: a case report. Br J Clin Pharmacol. 2010;69:703-4. DOI: https://doi.org/10.1111/j.1365-2125.2010.03651.x

Schmid DA, Depta JPH, Pichler WJ. T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity. Clin Exp Allergy J Br Soc Allergy Clin Immunol. 2006;36:59-69. DOI: https://doi.org/10.1111/j.1365-2222.2006.02402.x

Shiohara T, Mizukawa Y. Fixed drug eruption: a disease mediated by self-inflicted responses of intraepidermal T cells. Eur J Dermatol EJD. 2007;17:201-8.

Gupta R. Fixed Drug Eruption Due to Ornidazole. Indian J Dermatol. 2014;59:635. DOI: https://doi.org/10.4103/0019-5154.143591